메뉴 건너뛰기




Volumn 17, Issue 1, 2015, Pages 136-144

Malignant clinical features of anaplastic gliomas without IDH mutation

Author keywords

Anaplastic gliomas; CD133; Distant recurrence; Grade III gliomas; IDH

Indexed keywords

CD133 ANTIGEN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NESTIN; NIMUSTINE; PROTEIN P53; TRANSCRIPTION FACTOR SOX2; GLYCOPROTEIN; IDH1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PEPTIDE; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

EID: 84922547109     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou112     Document Type: Article
Times cited : (18)

References (43)
  • 1
    • 34547122001 scopus 로고    scopus 로고
    • The 2007 WHO classification of tumours of the central nervous system
    • Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
    • (2007) Acta Neuropathol , vol.114 , Issue.2 , pp. 97-109
    • Louis, D.N.1    Ohgaki, H.2    Wiestler, O.D.3
  • 2
    • 56749156414 scopus 로고    scopus 로고
    • Analysis of the IDH1 codon 132 mutation in brain tumors
    • Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
    • (2008) Acta Neuropathol , vol.116 , Issue.6 , pp. 597-602
    • Balss, J.1    Meyer, J.2    Mueller, W.3
  • 3
    • 60849115270 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations in gliomas
    • Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
    • (2009) N Engl J Med , vol.360 , Issue.8 , pp. 765-773
    • Yan, H.1    Parsons, D.W.2    Jin, G.3
  • 4
    • 52949127312 scopus 로고    scopus 로고
    • An integrated genomic analysis of human glioblastoma multiforme
    • Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
    • (2008) Science , vol.321 , Issue.5897 , pp. 1807-1812
    • Parsons, D.W.1    Jones, S.2    Zhang, X.3
  • 5
    • 65349150503 scopus 로고    scopus 로고
    • IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
    • Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
    • (2009) Am J Pathol , vol.174 , Issue.4 , pp. 1149-1153
    • Watanabe, T.1    Nobusawa, S.2    Kleihues, P.3
  • 6
    • 73649088347 scopus 로고    scopus 로고
    • Mutant metabolic enzymes are at the origin of gliomas
    • Yan H, Bigner DD, Velculescu V, et al. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69(24):9157-9159.
    • (2009) Cancer Res , vol.69 , Issue.24 , pp. 9157-9159
    • Yan, H.1    Bigner, D.D.2    Velculescu, V.3
  • 7
    • 70449711757 scopus 로고    scopus 로고
    • Genetic alterations and signaling pathways in the evolution of gliomas
    • Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2235-2241.
    • (2009) Cancer Sci , vol.100 , Issue.12 , pp. 2235-2241
    • Ohgaki, H.1    Kleihues, P.2
  • 8
    • 68349116524 scopus 로고    scopus 로고
    • IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
    • Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341-347.
    • (2009) Neuro Oncol , vol.11 , Issue.4 , pp. 341-347
    • Ichimura, K.1    Pearson, D.M.2    Kocialkowski, S.3
  • 9
    • 84859712831 scopus 로고    scopus 로고
    • Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
    • Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103(3):587-592.
    • (2012) Cancer Sci , vol.103 , Issue.3 , pp. 587-592
    • Mukasa, A.1    Takayanagi, S.2    Saito, K.3
  • 10
    • 84879540566 scopus 로고    scopus 로고
    • IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
    • Shibahara I, Sonoda Y, Kanamori M, et al. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol. 2012;17(6):551-561.
    • (2012) Int J Clin Oncol , vol.17 , Issue.6 , pp. 551-561
    • Shibahara, I.1    Sonoda, Y.2    Kanamori, M.3
  • 11
    • 77649122144 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
    • van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-1604.
    • (2010) Clin Cancer Res , vol.16 , Issue.5 , pp. 1597-1604
    • Van Den Bent, M.J.1    Dubbink, H.J.2    Marie, Y.3
  • 12
    • 80052712328 scopus 로고    scopus 로고
    • New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status
    • Shibahara I, Sonoda Y, Kanamori M, et al. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathol. 2011;28(3):203-208.
    • (2011) Brain Tumor Pathol , vol.28 , Issue.3 , pp. 203-208
    • Shibahara, I.1    Sonoda, Y.2    Kanamori, M.3
  • 13
    • 78651082266 scopus 로고    scopus 로고
    • Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas
    • Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
    • (2010) Acta Neuropathol , vol.120 , Issue.6 , pp. 707-718
    • Hartmann, C.1    Hentschel, B.2    Wick, W.3
  • 14
    • 0141842674 scopus 로고    scopus 로고
    • Identification of a cancer stem cell in human brain tumors
    • Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18): 5821-5828.
    • (2003) Cancer Res , vol.63 , Issue.18 , pp. 5821-5828
    • Singh, S.K.1    Clarke, I.D.2    Terasaki, M.3
  • 15
    • 9244241576 scopus 로고    scopus 로고
    • Identification of human brain tumour initiating cells
    • Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.
    • (2004) Nature , vol.432 , Issue.7015 , pp. 396-401
    • Singh, S.K.1    Hawkins, C.2    Clarke, I.D.3
  • 16
    • 0035499267 scopus 로고    scopus 로고
    • Stem cells, cancer, and cancer stem cells
    • Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
    • (2001) Nature , vol.414 , Issue.6859 , pp. 105-111
    • Reya, T.1    Morrison, S.J.2    Clarke, M.F.3
  • 17
    • 34247212827 scopus 로고    scopus 로고
    • Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
    • Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96(8):1293-1301.
    • (2007) Br J Cancer , vol.96 , Issue.8 , pp. 1293-1301
    • Schmitz, M.1    Temme, A.2    Senner, V.3
  • 18
    • 84865208822 scopus 로고    scopus 로고
    • Nestin expression in brain tumors: Its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas
    • Arai H, Ikota H, Sugawara K, et al. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol. 2012; 29(3):160-167.
    • (2012) Brain Tumor Pathol , vol.29 , Issue.3 , pp. 160-167
    • Arai, H.1    Ikota, H.2    Sugawara, K.3
  • 19
    • 79952119592 scopus 로고    scopus 로고
    • A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations
    • Yan X, Ma L, Yi D, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc NatlAcad Sci USA. 2011;108(4):1591-1596.
    • (2011) Proc NatlAcad Sci USA , vol.108 , Issue.4 , pp. 1591-1596
    • Yan, X.1    Ma, L.2    Yi, D.3
  • 20
    • 40749155451 scopus 로고    scopus 로고
    • Stem cell marker CD133 affects clinical outcome in glioma patients
    • Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008; 14(1):123-129.
    • (2008) Clin Cancer Res , vol.14 , Issue.1 , pp. 123-129
    • Zeppernick, F.1    Ahmadi, R.2    Campos, B.3
  • 21
    • 84883186250 scopus 로고    scopus 로고
    • The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence
    • Shibahara I, Sonoda Y, Saito R, et al. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol. 2013;15(9):1151-1159.
    • (2013) Neuro Oncol , vol.15 , Issue.9 , pp. 1151-1159
    • Shibahara, I.1    Sonoda, Y.2    Saito, R.3
  • 22
    • 77949653208 scopus 로고    scopus 로고
    • Association of stem cell marker CD133 expression with dissemination of glioblastomas
    • Sato A, Sakurada K, Kumabe T, et al. Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg Rev. 2010;33(2):175-183.
    • (2010) Neurosurg Rev , vol.33 , Issue.2 , pp. 175-183
    • Sato, A.1    Sakurada, K.2    Kumabe, T.3
  • 23
    • 72149119461 scopus 로고    scopus 로고
    • Presence of pluripotent CD133+ cells correlates with malignancy of gliomas
    • Thon N, Damianoff K, Hegermann J, et al. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci. 2010;43(1):51-59.
    • (2010) Mol Cell Neurosci , vol.43 , Issue.1 , pp. 51-59
    • Thon, N.1    Damianoff, K.2    Hegermann, J.3
  • 24
    • 60149107175 scopus 로고    scopus 로고
    • Nestin and CD133: Valuable stem cell-specific markers for determining clinical outcome of glioma patients
    • Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008;27:85.
    • (2008) J Exp Clin Cancer Res , vol.27 , pp. 85
    • Zhang, M.1    Song, T.2    Yang, L.3
  • 25
    • 79956363309 scopus 로고    scopus 로고
    • SOX2 expression and amplification in gliomas and glioma cell lines
    • Annovazzi L, Mellai M, Caldera V, et al. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics & Proteomics. 2011;8(3):139-147.
    • (2011) Cancer Genomics & Proteomics , vol.8 , Issue.3 , pp. 139-147
    • Annovazzi, L.1    Mellai, M.2    Caldera, V.3
  • 26
    • 84876176586 scopus 로고    scopus 로고
    • Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels
    • Galatro TF, Uno M, Oba-Shinjo SM, et al. Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels. PloS One. 2013;8(4):e61605.
    • (2013) PloS One , vol.8 , Issue.4 , pp. e61605
    • Galatro, T.F.1    Uno, M.2    Oba-Shinjo, S.M.3
  • 27
    • 34447625239 scopus 로고    scopus 로고
    • Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: Correlation of nestin with prognosis of patient survival
    • Strojnik T, Rosland GV, Sakariassen PO, et al. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol. 2007;68(2):133-143.
    • (2007) Surg Neurol , vol.68 , Issue.2 , pp. 133-143
    • Strojnik, T.1    Rosland, G.V.2    Sakariassen, P.O.3
  • 28
    • 79951486845 scopus 로고    scopus 로고
    • Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
    • Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76(5):432-437.
    • (2011) Neurology , vol.76 , Issue.5 , pp. 432-437
    • Pope, W.B.1    Xia, Q.2    Paton, V.E.3
  • 29
    • 78651322039 scopus 로고    scopus 로고
    • Radiographic patterns of relapse in glioblastoma
    • Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol. 2011;101(2):319-323.
    • (2011) J Neurooncol , vol.101 , Issue.2 , pp. 319-323
    • Chamberlain, M.C.1
  • 30
    • 70449521966 scopus 로고    scopus 로고
    • Long-term survivors of glioblastoma: Clinical features and molecular analysis
    • Sonoda Y, Kumabe T, Watanabe M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien). 2009;151(11):1349-1358.
    • (2009) Acta Neurochir (Wien) , vol.151 , Issue.11 , pp. 1349-1358
    • Sonoda, Y.1    Kumabe, T.2    Watanabe, M.3
  • 31
    • 70349594347 scopus 로고    scopus 로고
    • Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
    • Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100(10): 1996-1998.
    • (2009) Cancer Sci , vol.100 , Issue.10 , pp. 1996-1998
    • Sonoda, Y.1    Kumabe, T.2    Nakamura, T.3
  • 32
    • 77955716591 scopus 로고    scopus 로고
    • O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
    • Sonoda Y, Yokosawa M, Saito R, et al. O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 2010;15(4):352-358.
    • (2010) Int J Clin Oncol , vol.15 , Issue.4 , pp. 352-358
    • Sonoda, Y.1    Yokosawa, M.2    Saito, R.3
  • 33
    • 48749114753 scopus 로고    scopus 로고
    • Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas
    • Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008;88(8):808-815.
    • (2008) Lab Invest , vol.88 , Issue.8 , pp. 808-815
    • Joo, K.M.1    Kim, S.Y.2    Jin, X.3
  • 34
    • 80052709582 scopus 로고    scopus 로고
    • Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution
    • Metellus P, Nanni-Metellus I, Delfino C, et al. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol. 2011;18(10):2937-2945.
    • (2011) Ann Surg Oncol , vol.18 , Issue.10 , pp. 2937-2945
    • Metellus, P.1    Nanni-Metellus, I.2    Delfino, C.3
  • 35
    • 58149456505 scopus 로고    scopus 로고
    • Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    • Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
    • (2009) J Neurooncol , vol.91 , Issue.3 , pp. 329-336
    • Zuniga, R.M.1    Torcuator, R.2    Jain, R.3
  • 36
    • 62449258056 scopus 로고    scopus 로고
    • Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status
    • Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009;27(8): 1275-1279.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1275-1279
    • Brandes, A.A.1    Tosoni, A.2    Franceschi, E.3
  • 37
    • 77956227086 scopus 로고    scopus 로고
    • Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinicians perspective
    • van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinicians perspective. Acta Neuropathol. 2010;120(3):297-304.
    • (2010) Acta Neuropathol , vol.120 , Issue.3 , pp. 297-304
    • Van Den Bent, M.J.1
  • 38
    • 33845317573 scopus 로고    scopus 로고
    • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    • Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
    • (2006) Nature , vol.444 , Issue.7120 , pp. 756-760
    • Bao, S.1    Wu, Q.2    McLendon, R.E.3
  • 39
    • 46449115281 scopus 로고    scopus 로고
    • Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    • Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18): 3015-3024.
    • (2008) J Clin Oncol , vol.26 , Issue.18 , pp. 3015-3024
    • Murat, A.1    Migliavacca, E.2    Gorlia, T.3
  • 40
    • 44649137314 scopus 로고    scopus 로고
    • CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors
    • Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 2008;18(3):370-377.
    • (2008) Brain Pathol , vol.18 , Issue.3 , pp. 370-377
    • Beier, D.1    Wischhusen, J.2    Dietmaier, W.3
  • 41
    • 84857065790 scopus 로고    scopus 로고
    • Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR
    • Yoshimoto K, Ma X, Guan Y, et al. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol. 2011;28(4):291-296.
    • (2011) Brain Tumor Pathol , vol.28 , Issue.4 , pp. 291-296
    • Yoshimoto, K.1    Ma, X.2    Guan, Y.3
  • 42
    • 78650705036 scopus 로고    scopus 로고
    • Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis
    • Pallini R, Ricci-Vitiani L, Montano N, et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117(1):162-174.
    • (2011) Cancer , vol.117 , Issue.1 , pp. 162-174
    • Pallini, R.1    Ricci-Vitiani, L.2    Montano, N.3
  • 43
    • 34249332411 scopus 로고    scopus 로고
    • CD133(+) and CD133(2) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
    • Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(2) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9): 4010-4015.
    • (2007) Cancer Res , vol.67 , Issue.9 , pp. 4010-4015
    • Beier, D.1    Hau, P.2    Proescholdt, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.